Evidence map›Paper›PMID 39732949›Full record

ArticleScientific reports2024

The role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still's disease, and COVID-19 cytokine storm.

Mariam Goubran, Caroline Spaner, Sophie Stukas, Adi Zoref-Lorenz, Kamran Shojania, Madelaine Beckett, Amanda Li, Erica Peterson, Mypinder Sekhon, Rebecca Grey and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Expert Perspective: Diagnosis and Treatment of Castleman Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mariam Goubran *Department of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-9181-379X
Caroline Spaner *Department of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-1446-9582
Sophie StukasDepartment of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Adi Zoref-LorenzFaculty of Medicine, Hematology Institute, Meir Medical Center, Tel Aviv University, Tel Aviv, Israel.
Kamran ShojaniaDivision of Rheumatology, Department of Medicine, Vancouver General Hospital, Vancouver, BC, Canada.ORCID 0000-0003-2525-3744
Madelaine BeckettDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-3050-9292
Amanda LiDivision of Pediatric Hematology, Oncology, and BMT, University of British Columbia, British Columbia Children's Hospital, Vancouver, BC, Canada.
Erica PetersonDivision of Hematology, Department of Medicine, Vancouver General Hospital, Vancouver, BC, Canada.
Mypinder SekhonDivision of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Rebecca GreyDivision of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Cheryl WellingtonDepartment of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Catherine V ChengDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Catherine M BiggsDivision of Allergy and Immunology, University of British Columbia, Vancouver, BC, Canada.
Andre MattmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Michael B JordanFaculty of Medicine, Hematology Institute, Meir Medical Center, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0003-4207-3542
Luke Y C ChenDivision of Hematology, Department of Medicine, Vancouver General Hospital, Vancouver, BC, Canada. lchen2@bccancer.bc.ca.ORCID 0000-0002-9551-2951
Audi SetiadiInternational Collaboration On Repair Discoveries, School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada. audi.setiadi@cw.bc.ca.ORCID 0000-0002-2361-7391

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine storm syndromes such as hemophagocytic lymphohistiocytosis (HLH), Adult-onset Still's disease (AOSD), and COVID-19 cytokine storm (CCS) are characterized by markedly elevated inflammatory cytokines. However clinical measurement of serum cytokines is not widely available. This study examined the clinical utility of C-reactive protein (CRP) and ferritin, two inexpensive and widely available inflammatory markers, for distinguishing HLH from AOSD and CCS. This single centre retrospective study included 44 secondary HLH patients, 14 AOSD patients, and 13 CCS patients. Baseline CRP and ferritin measured within 72 h of diagnosis and before administration of corticosteroids or other anti-inflammatory therapies were analyzed. The median CRP in HLH patients was lower than AOSD (71 mg/L vs. 172 mg/L, p < 0.001) and CCS (71 mg/L vs. 121 mg/L, p = 0.0095) patients. Serum ferritin levels were lower in CCS compared to HLH (1,386 µg/L vs. 29,019 µg/L, p < 0.001) and AOSD (11,359 µg/L vs. 29,019 µg/L, p = 0.035). A CRP < 130 mg/L when combined with an HScore > 136 improves the specificity of HScore alone for HLH from 85.2 to 96.3%. Adding CRP < 130 mg/L to ferritin > 15,254 µg/L increases specificity for HLH from 88.9 to 100%. This study demonstrates that median CRP is lower in HLH than in AOSD and CCS, and median ferritin is lower in CCS than in HLH or AOSD. This study demonstrates the clinical utility of these widely available inflammatory markers for distinguishing between different cytokine storm syndromes.

Indexed as

BiomarkersCOVID-19C-Reactive ProteinCytokine Release SyndromeFerritinsLymphohistiocytosis, HemophagocyticStill's Disease, Adult-OnsetAdultAgedDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2BiomarkersC-Reactive ProteinFerritinsFerritinHemophagocytic syndromeHLHMalignancy-associated HLHSoluble interleukin-2 receptor

Identifiers

PMID39732949
PMCPMC11682105

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.